anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To prevent a misdiagnosis by a physician by estimating a solution of an intracardiac electrical phenomenon based on an electrocardiogram, calculating an evaluation value of the estimated solution, comparing the evaluation value with a prescribed threshold value, deciding whether the solution is reliable or not and displaying the solution according to the decision result. SOLUTION: A magnetocardiography of a subject is measured (S1). From distribution and time waveform on the breast surface in measured magnetic field, excitation time distribution and action potential amplitude distribution within a heart are estimated (S2). An evaluation value (f) for reflecting whether estimated distributions are reliable as a solution of an electrical phenomenon within the heart or not is calculated (S5) and the evaluation value (f) is compared with a preliminarily set threshold value (S6). When the evaluation value (f) is equal to the threshold value and below, the value is decided as an estimation result defective (S6), an error display to the effect that the solution is decided to be non-reliable is performed (S9) and only a reliable estimation result is displayed to a user such as a physician.  As a result, the estimated solution is not displayed without discrimination and an erroneous diagnosis by the physician can be prevented.
Corneal transplantation has evolved rapidly in recent years. Lamellar keratoplasty to replace diseased endothelium has led to faster recovery times, fewer complications, and better visual acuity outcomes. Currently, Descemet's Stripping Endothelial Keratoplasty (DSAEK) is the most common procedure because of its relative ease and good outcomes. Newer techniques such as Descemet's Membrane Endothelial Keratoplasty (DMEK), where Descemet's membrane alone is transplanted, has the potential to further improve visual acuity outcomes, produce fewer higher-order corneal aberrations and decrease rejection rates. However, donor preparation, increased intra-operative times, and problems with donor attachment in DMEK are all important limitations.

There are three potential mechanisms by which DMEK may provide better visual acuity outcomes than DSAEK; graft thickness, interface haze and corneal higher-order aberrations. Graft thickness has been correlated with best spectacle corrected visual acuity (BSCVA) outcomes among thinner grafts. One retrospective case series found that 71% of thin endothelial grafts (defined as \<131μm) had BSCVA of 20/25 or better while only 50% of thick grafts (defined as ≥131) achieved this. In addition, higher-order aberrations, in particular of the posterior cornea, are increased after DSAEK. Theoretically, given the decreased tissue transplanted after DMEK this would be lessened, however, one retrospective series looking at higher order aberrations in DMEK compared with DSAEK found no difference in posterior aberrations of the central 4.0 mm zone between the two groups. Finally, interface haze may be increased in DSAEK and has been correlated with BSCVA.

Ultrathin DSAEK involves donor preparation with a deep microkeratome pass to produce donor grafts less than 100 um thick. This procedure may have similar results to DMEK but without the technical difficulties. Several large prospective series show similar visual outcome results and rates of immunologic rejection between ultrathin DSAEK and DMEK, however comparisons are difficult. This comparative effectiveness clinical trial could directly address these important issues. The investigators also anticipate that secondary analyses of the trial data will allow us to address several more.
The purpose of this multicenter, randomized, controlled clinical study was to evaluate the efficacy and safety of propofol compared with normal saline and dexmedetomidine in the effect of postoperative sleep quality in elderly subjects with sleep disorders. Subjects were randomly assigned to propofol group, dexmedetomidine group or normal saline control group. Propofol group: At 21:00 on the night of tracheal extubation, propofol was administered intravenously. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.Dexmedetomidine group: treated with dexmedetomidine at 21 PM on the day of tracheal extubation. During administration, patients were evaluated with MOAA/S every 2min. Normal saline control group: 21 on the night of tracheal extubation: Normal saline was injected intravenously at the rate of 0.5ml/(kg.h) beginning at 00. During the administration, patients were evaluated with MOAA/S every 2min. The effect of drugs on sleep improvement was evaluated by subjective scale and objective electrical monitoring.
Psoriasis is a prevalent condition characterized by chronic inflammation, immune dysregulation, and genetic alterations, significantly impacting the well-being of affected individuals. Recently, a novel aspect of programmed cell death, ferroptosis, linked to iron metabolism, has come to light. This research endeavors to unveil novel diagnostic genes associated with ferroptosis in psoriasis, employing bioinformatic methods and experimental validation. Diverse analytical strategies, including "limma," Weighted Gene Co-expression Network Analysis (WGCNA), Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine Recursive Feature Elimination (SVM-RFE), and Random Forest (RF), were employed to pinpoint pivotal ferroptosis-related diagnostic genes (FRDGs) in the training datasets GSE30999, testing dataset GSE41662 and GSE14905. The discriminative potential of FRDGs in distinguishing between normal and psoriatic patients was gauged using Receiver Operating Characteristic (ROC) curves, while the functional pathways of FRDGs were scrutinized through Gene Set Enrichment Analysis (GSEA). Spearman correlation and ssGSEA analysis were applied to explore correlations between FRDGs and immune cell infiltration or oxidative stress-related pathways. The study identified six robust FRDGs - PPARD, MAPK14, PARP9, POR, CDCA3, and PDK4 - which collectively formed a model boasting an exceptional AUC value of 0.994. GSEA analysis uncovered their active involvement in psoriasis-related pathways, and substantial correlations with immune cells and oxidative stress were noted. In vivo, experiments confirmed the consistency of the six FRDGs in the psoriasis model with microarray results. In vitro, genetic knockdown or inhibition of MAPK14 using SW203580 in keratinocytes attenuated ferroptosis and reduced the expression of inflammatory cytokines. Furthermore, the study revealed that intercellular communication between keratinocytes and macrophages was augmented by ferroptotic keratinocytes, increased M1 polarization, and recruitment of macrophage was regulated by MAPK14. In summary, our findings unveil novel ferroptosis-related targets and enhance the understanding of inflammatory responses in psoriasis. Targeting MAPK14 signaling in keratinocytes emerges as a promising therapeutic approach for managing psoriasis.
Retrospective review of routine program data for child contacts less than five years of adult TB index cases who are receiving TB care at local, decentralized clinics in the Matlosana district of Northwest Province will be assessed. 16 clinics will be stratified and randomized in 1:1 fashion to either TST-based screening, the current standard of care, or symptom-based screening, the newly recommended standard of care in South Africa. Those who are TST positive in the TST-based group and those who are symptomatic in the symptom-based group will be referred to Klerkdorp Hospital for further evaluation of tuberculosis. Nurses in the decentralized clinics will initiate those who are TST negative or asymptomatic on IPT. Their clinical course will be monitored throughout treatment and adherence to therapy measured. The investigators will compare clinic-level outcomes including percentage of patients initiated on, adherent to, and completing IPT.
A method of production and composition of a humic substances-based topical gel that contains a high concentration of polymerized humic substances in the form of polyelectrolyte-enhanced biopolymers, allowing for targeted application of gel to skin. A method of production consists of selection of humic substances containing material, extraction of humic substances from the material, polymerization of humic substances, and further processing for product preservation. Such humic substances based material may be derived from brown coal, such as leonardite or lignite, or peat. An extraction technique for extraction of the humic substances is an alkali extraction method. Such a resulting composition may contain sodium silicate as a gelling agent for ease of application, and in some embodiments a preservative or combination of preservatives for shelf life. Such a humic substances-based topic gel is water soluble, allowing for in-home application and ability to discard through washing down a household drain.
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
A coating for an implant surface comprising one or more nanoparticles of less than or equal to 500 nanometers and an implant surface capable of receiving the nanoparticles, the implant selected from the group consisting of metal, carbon, graphite, polymer, protein, nucleic acid, microorganisms, hydrogel, liquid, porous and polymer blend particles, and combinations thereof. The coating promotes characteristics on the implant surface such as reducing protein unfolding, preventing inflammatory and fibrotic cell accumulation, reducing the number of such cell attachment sites and preventing other adverse biological reactions. The coating may be applied on any material via physical and/or chemical binding. The coating may further comprise a surfactant and may include a tag, adsorbed, absorbed or incorporated onto the nanoparticle. The coating on an implant surface is used for purposes that may be cosmetic, therapeutic, preventative, reconstructive, monitoring and replacement. The coating may also be used for in vitro purposes.
PROBLEM TO BE SOLVED: To obtain a two-pack mixing type portable type continuous peritoneal dialysis pharmaceutical prepn. used for a dialysis treatment and more particularly a portable type continuous peritoneal dialysis(CAPD) thereby utilizing a peritoneum. SOLUTION: This two-pack mixing type portable type continuous peritoneal dialysis pharmaceutical prepn. has a bag 2 for the pharmaceutical prepn. and a bag 3 for waste liquid and is formed by packing the content drugs to be packed into both of the bag 2 for the pharmaceutical prepn. and the bag 3 for the waste liquid. The content drugs to be packed into both of the bag 2 for the pharmaceutical prepn. and the bag 3 for the waste liquid are the same peritoneal dialyzate or a glucose-contg. liquid or calcium-contg. liquid or the like is packed into either one bag and a buffer agent-contg. liquid or sodium bicarbonate-contg. liquid or the like is packed into the other bag.
Four hundred consenting treatment drug court participants will be randomly assigned to either an HIV intervention group (n = 200) or an attention control group. All clients will attend their regularly scheduled status hearings which are scheduled approximately every six weeks. Clients in the HIV intervention group will receive a brief computerized, self-administered HIV risk reduction intervention following each of their first three status hearings. Clients in the attention control condition will view a series of educational life-skill videos of matched length following each of their first three status hearings. The primary outcome will be engagement in high risk behaviors as measured by the Risk Assessment Battery (RAB). Secondary HIV-related outcomes will include: (1) rate of HIV testing, (2) condom procurement, and (3) self-reported condom use. Tertiary outcomes related to treatment court compliance will include: (1) drug court graduation, (2) urinalysis-confirmed drug abstinence, (3) case management attendance, and (4) satisfaction with case management. In addition, we will conduct preliminary cost and cost-effectiveness analyses on the delivery of the brief computerized HIV intervention. Assessments will be conducted at baseline and 9- and 15-months post admission.
A patient monitoring system comprises a plurality of sensors and an analysis computing entity. The sensors comprise a visual sensor and a wearable sensor. The visual sensor is configured to capture images of a patient and provide the images of the patient such that the analysis computing entity receives the images. The wearable sensor is configured to capture wearable data. The wearable data comprises (a) biometric data of the patient and/or (b) movement data of the patient. The wearable sensor is configured to provide the wearable data such that the analysis computing entity receives the wearable data. The analysis computing entity is configured to receive the images of the patient and the wearable data, analyze at least one of the images of the patient and the wearable data to determine objective patient data, and update a patient record based on the objective patient data.
The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine).
Provided are methods and compositions for the therapeutic delivery of angiogenesis-regulating factors to in vivo sites in need thereof. The methods and compositions relate generally to the use of platelets bearing one or more exogenous angiogenesis regulating factors. In one aspect, described are methods of delivering an angiogenesis-regulating factor, the method comprising contacting a tissue with a composition comprising isolated platelets comprising an exogenous angiogenesis regulating factor. The methods can be employed for example, to enhance wound healing, or alternatively, to inhibit tumor growth. In another aspect, therapeutic platelet compositions and kits are provided in which the platelets bear one or more exogenous angiogenesis regulating factors. Also provided are methods of modulating the release angiogenesis promoting and inhibiting factors by platelets using agonists and/or antagonists of platelet protease-activated receptors PAR-1 and PAR-4.
The NAFLD registry is a local database provided by the principal investigator, Dr. J. Allard, which will be stored on the Research Intranet at the University Health Network, Toronto. The database will be password protected. Only clinic personnel and members of Dr. Allard's research team involved in the study will have access to the database. A code and date of birth will be used to identify each patient. All patients entering the NAFLD clinic at Toronto General Hospital will be consented for the registry. Only data from their regular clinic visits will be used for entry into the registry. Data entered into the registry will include: 1) Patient demography: age, sex, ethnicity, medical history; 2) Anthropometry: weight, height, BMI, waist circumference; 3) Nutritional assessment: Food records and food frequency questionnaires are kept by the subjects and data will be analyzed to assess the intake of macro- and micronutrients. Amount of alcohol and number of cigarette smoked will also be recorded; 4) Physical Activity will be assessed using the Paffenbarger Physical Activity Questionnaire; 5) Medications: insulin, non-steroidal anti-inflammatory drugs, corticosteroids, statins, medications used to treat diabetes/obesity (e.g. metformin, thiazolidinediones, orlistat...), medication to treat liver disease (eg. urso, carnitine, choline...), antioxidant vitamin or fish oil supplementation; 6) Blood work, currently including: complete blood count, biochemistry including liver enzymes, total protein, albumin, glucose, insulin, and blood lipid profile; other diagnostic blood work done to exclude other causes of liver disease, e.g. ceruloplasmin, anti-smooth muscle antibodies,... One plasma sample will be stored for assessment of cytokeratin 18 (CK-18) fragments as a novel marker for NASH in patients with NAFLD; 7) Presence of metabolic syndrome; 8) Disease categorization: SS, NASH, cirrhosis; 9) Survival: alive, death: causes, NAFLD-related or not NAFLD-related; 10) Liver biopsy results, NAFLD fibrosis score, and elastography results.

Data will be entered after every clinic visit. Case report forms will be used to collect the data from the patient charts and facilitate data input into the registry database All patients will be followed prospectively until withdrawal from the clinic or death. Descriptive statistics will be performed. For the entire NAFLD population, probability of survival, cirrhosis, as well as liver and non-liver related morbidity will be calculated using the Kaplan Meier method.
Trapezius myalgiais the complaint of pain, stiffness, and tightness of the upper trapezius muscle. It is characterised by acute or persistent neck-shoulder pain. In today's society, due to the increased use of computers, where the neck and shoulders are maintained in static abnormal postures to look at the computer screens and become vulnerable to cause neck pain. The aim of the study is to determine effects of upper trapezius stretching with and without mid lower trapezius strengthening exercises on pain, disability and quality of life in females with work related trapezius myalgia.

A Randomized controlled trial will be conducted in physiotherapy outpatient department of Bahria International Hospital Lahore. Non-probability convnience sampling will be used to collect the data. Sample size of 42 subjects with age group between 18 to 40 years will be taken. Data will be collected by using tools Numeric Pain Rate Scale (NPRS) for pain, Neck Disability Index (NDI) for disability and SF-36 for Quality of life. An informed consent will be taken. A total of 20 subjects will be selected by following inclusion and exclusion criteria and will equally divided in to two groups by random number generator table. Both groups will come thrice per week for a total of 4 weeks. The data will be analysed using SPSS software version 25. After assessing normality of data by Shapiro-Wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.
This group will not be provided any program for the initial 4 weeks. After they complete the week 5 assessments, they will have the option to complete the Attention Training.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition capable of imparting moistness to skin by humectant effects possessed thereby, exhibiting beautifying and whitening effects by an antityrosinase activity possessed thereby, useful for suppressing or treating pigmentation such as dermal stains, ephelides or dark skin causing problems in beauty culture and capable of providing white and beautiful skin. SOLUTION: The characteristic of this cosmetic composition is to contain Valeriana sambucifolia Mikan var. fauriei Hara and/or its extract. The Valeriana sambucifolia Mikan var. fauriei Hara is a perennial herb of the family Valerianaceae and is distributed in wet mountainous districts of Hokkaido to Kyushu in Japan and further the northeastern section of China, the Korean Penninsula and Taiwan. The height of stems is 30-100 cm and the Valeriana sambucifolia Mikan var. fauriei Hara puts forth pink flowers in a corymbous state in the tip thereof from May.
PROBLEM TO BE SOLVED: To obtain a new piericidin derivative having a cytokine production- inhibiting action and effective for allergic diseases, autoimmune diseases, rejection symptoms accompanied by organ transplantation, etc. SOLUTION: This piericidin derivative is expressed by the formula (R is H, methyl) or its salt. The compound of the formula is obtained by culturing Streptomyces SP Q39071 (FERM P-15272) in a culture medium under an aerobic condition, extracting the compound from the culture product and then purifying the compound. The compound of the formula has an excellent inhibition action on the production of cytokines such as interleukin-2, interleukin-4, interleukin-5, γ-interferon, etc., in T cells. The compound of the formula can be processed into preparations by conventional methods. The compound of the formula is orally administered at a daily dose of 0.01-1,000mg/adult, and also administered at a dose of 0.001-10mg/kg/adult/time in parenteral administrations excluding the administrations for external uses, e.g. in an intravenous injection. An external use agent, e.g. an ointment containing the active ingredient in a concentration of 0.03-0.3% is coated on skin once to several times a day.
1498119 Vegetable extracts SOC DES PRODUITS NESTLE SA 31 Oct 1975 [17 Dec 1974] 45238/75 Heading A2B Vegetable extracts which dissolve instantaneously in water e.g. coffee, chicory, tea and herbel decoctions have a density of 50-300 gm/litre and have a porous continuous structure and a smooth surface. The grains may be 1 to 15mm. in diameter and have a crushing strength of 2.5 to 7.5 Newtons. The moisture content may be up to 6% and the extract may be capable of absorbing up to 20% by weight of fats. The extracts may be made by extruding under pressure of 1-10 bars in powder or paste form into a subatmospheric pressure of 0.01-0.3 bars and cutting into fragments (the paste containing up to 10% water), at 60-125C. The herbal decoctions may be mint, lime blossom, vervain or camomile. Reference is made to Specification 1498120.
BACKGROUND: Glycated albumin (GA) has shown promise in predicting risk of adverse neonatal outcomes (ANO) in pregnant women with type 2 diabetes (T2DM) and gestational diabetes (GDM). However, previous studies showing a negative correlation between GA and body mass index (BMI) suggest that lower predictive cutoffs may be needed in populations with elevated BMI.
METHODS: We performed a case-control study of prospectively enrolled pregnant women with T2DM or GDM and BMI ≥25 kg/m2 matched to biobanked controls without diabetes. Serum collected during the second and/or third trimesters was used to measure the percentage of GA (% GA). Receiver operating characteristic (ROC) curves were used to examine % GA to predict an ANO composite, including macrosomia, hypoglycemia, respiratory distress syndrome, and/or hyperbilirubinemia for the second and third trimesters.
RESULTS: The median BMIs for cases and controls were 34.0 and 31.0 kg/m2, respectively. The area under the ROC curve to predict the ANO composite was significant for second trimester values but ambiguous for third trimester due to its wide 95% CI. A cutoff of 12.3% GA during second trimester showed 100% sensitivity and 73% specificity. Transference of previously published reference ranges did not validate, suggesting lower ranges are needed for women with overweight/obesity.
CONCLUSIONS: In this pilot study, % GA shows promise to stratify pregnant patients with diabetes and obesity into risk categories for ANO with excellent predictive ability in the second trimester. If this holds in larger studies, using second trimester % GA could allow additional intervention to improve blood glucose control and minimize ANO.